The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of atezolizumab (ATEZO) and bevacizumab (BEV) in combination with Y90 TARE in patients (pts) with hepatocellular carcinoma (HCC): Y90+/- BEAT.
 
Renuka V. Iyer
Consulting or Advisory Role - Advanced Accelerator Applications; AstraZeneca; Bayer; Eisai; Exelixis; Ipsen; Lexicon; Merck; Novartis; QED therapeutics; Sandoz; Sun pharma; Tersera
Research Funding - Cleveland BioLabs (Inst); Genentech/Roche (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Michael Petroziello
No Relationships to Disclose
 
Nainesh Parikh
No Relationships to Disclose
 
Richard D. Kim
Consulting or Advisory Role - Bayer; Exelixis; Lilly; Pfizer; QED Therapeutics; Roche/Genentech; SERVIER; Taiho Oncology
Speakers' Bureau - Eisai; Exelixis; Incyte
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst)
 
Thatcher Ross Heumann
No Relationships to Disclose
 
Daniel Brown
No Relationships to Disclose
 
Kevin Kim
No Relationships to Disclose
 
Yixing Jiang
No Relationships to Disclose
 
Suvranu Ganguli
No Relationships to Disclose
 
Eric Marks
No Relationships to Disclose
 
Beau Toskich
Stock and Other Ownership Interests - Vivos Therapeutics
Honoraria - Boston Scientific (Inst); BTG (Inst)
Consulting or Advisory Role - AstraZeneca (Inst); Boston Scientific (Inst); Eisai (Inst); Genentech (Inst); Histosonics (Inst); Johnson & Johnson (Inst); Sirtex Medical (Inst)
Research Funding - AstraZeneca (Inst); Boston Scientific (Inst); Genentech (Inst); Johnson and Johnson (Inst)
Travel, Accommodations, Expenses - Boston Scientific (Inst)
 
Umair Majeed
No Relationships to Disclose
 
Shamar Young
No Relationships to Disclose
 
Rachna T. Shroff
Consulting or Advisory Role - AstraZeneca; Basilea; Boehringer Ingelheim; Exelixis; Genentech; Incyte; Merck; QED Therapeutics; SERVIER; Taiho Pharmaceutical
Research Funding - Bayer; Bristol-Myers Squibb; Exelixis; Faeth Therapeutics; Immunovaccine; Loxo/Lilly; Merck; NGM Biopharmaceuticals; Novocure; Nucana; Pieris Pharmaceuticals; QED Therapeutics; Rafael Pharmaceuticals; Seagen; Taiho Pharmaceutical
 
Moh'd M. Khushman
Stock and Other Ownership Interests - Blueprint Medicines; Cardiff Oncology; Moderna Therapeutics; Regeneron
Consulting or Advisory Role - AstraZeneca; Bayer; Taiho Pharmaceutical
Speakers' Bureau - AstraZeneca; Caris Life Sciences; Pfizer
 
Andrew Gunn
No Relationships to Disclose
 
Filip Banovac
No Relationships to Disclose
 
Aiwu Ruth He
Consulting or Advisory Role - Eisai; Genentech/Roche; Merck
Speakers' Bureau - bms; Eisai; Exelixis
Research Funding - Genentech; Merck